Mechanism of tumor metastasis and tumor-suppressive role of UDP-glucose revealed

June 26, 2019

Scientists from Dalian Institute of Chemical Physics (DICP) and Shanghai Institute of Biochemistry and Cell Biology (SIBCB) of the Chinese Academy of Sciences revealed that UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Their findings were published in Nature.

Metastasis is the primary cause of cancer morbidity and mortality, and accounts for up to 95% of cancer-related deaths. UDP-glucose 6-dehydrogenase (UGDH) is a key enzyme in the uronic acid pathway that converts UDP-glucose to UDP-glucuronic acid; Hu antigen R (HuR) is a ubiquitously expressed RNA-binding protein that binds to the 3'-untranslated region (UTR) region of many short-lived mRNAs and increases their stability.

Dr. YANG Weiwei's group from SIBCB has performed the experimental research. The results show that, upon EGFR activation, phosphorylated UGDH interacts with HuR and converts UDP-glucose to UDP-glucuronic acid. The resulting UDP-glucoronic acid attenuated the UDP-glucose-mediated inhibition of the association of HuR with SNAI1 mRNA, thus enhancing SNAI1 mRNA stability.

Increased SNAIL expression initiates the epithelial-mesenchymal transition, thereby promoting tumor cell migration and lung cancer metastasis. These findings reveal a tumor-suppressive role for UDP-glucose in lung cancer metastasis and uncover the mechanism by which UGDH promotes tumor metastasis by increasing SNAI1 mRNA stability.

Dr. Li Guohui's group from DICP has performed molecular dynamics (MD) simulations to elucidate the structural basis underlying the UDP-Glc- or UDP-GlcUA-regulated binding of HuR to mRNA. The MD results showed that both UDP-Glc and UDP-GlcUA bound to the same RNA-binding domain of HuR.

The binding affinity of UDP-Glc with HuR is stronger than UDP-GlcUA with HuR, which is consistent with experimental results. Essentially, two mutants of HuR(Y63F) and HuR(N134A) were generated and studied. It was found that HuR(N134A) had a much lower affinity for both metabolites than HuR(WT) and HuR(Y63F), but still bound to SNAI1 mRNA, and tumor cells rescued with rHuR(N134A) showed more migration.
This research was supported by the State Key Laboratory of Molecular Reaction Dynamics, the Strategic Priority Research Program of the Chinese Academy of Sciences and the National Natural Science Foundation of China.

Chinese Academy of Sciences Headquarters

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to